ClinicalTrials.gg
CompletedNCT03733951Updated Jun 9, 2023

KN046 in Subjects With Advanced Solid Tumors and Lymphoma

A Phase 1 interventional study of KN046 in Advanced Solid Tumors and Lymphoma, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Completed at 13 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-09.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
139
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 275 studies in Lymphoma with a site in China — 102 open to participants now, 118 under way, 10 of them phase 3. Lymphoma · China.

Enrollment
45th of 232
139 · median 47
Started
2018
with 16 others
Phase 1
83 of 275
25 open now
Registered
84th of 275
by date

Among the 275 studies in Lymphoma with a site in China, this one is the 45th largest by enrollment of the 232 interventional ones that give a count, is one of 17 that started in 2018, is one of 83 in phase 1, and was the 84th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

102 of the 275 studies in Lymphoma with a site in China are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Lymphoma with a site in China, or all of them as a file.
02

Study summary

This is a phase Ia/Ib, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN046 in subjects with advanced solid tumors and lymphoma .

03

Conditions studied

  • Advanced Solid Tumors
  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed ; willing and able to complete all required procedures of study.
  2. With advanced-stage or tumor (unresectable) and experienced progression since last anti-tumor treatment; standard therapy is not available or rejected.
  3. Subjects must have at least one in advanced solid tumors, at least one measurable or assessable lesion in NK/T cell lymphoma.
  4. performance status of 0 or 1.
  5. Subject must have adequate organ function.
  6. Female patients and males with partners of should be using highly effective measures (failure rate of less than 1% per year). Contraception should be continued for a period of 24 weeks after dosing has been completed.
  7. Ability to comply with treatment, procedures and PK sample collection and the required study follow-up procedures.

Exclusion criteria

Exclusion Criteria:

  1. Known or other CNS metastasis that is either symptomatic or untreated.
  2. Is currently participating or has participated in a study of an drug within 4 weeks prior to the first dose of trial treatment.
  3. Patients who have received immune checkpoint proteins/antibody/medicine (including , PD-L1, etc) for treatment.
  4. Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous to assist with management.
  5. Subjects with active diseases or history of autoimmune diseases should be excluded.
  6. Active or infection.
  7. Known infection or known history of acquired immune deficient syndrome (AIDS).
  8. Any unresolved Grade ≥ 2 toxicities from prior anti-cancer therapy with the exception of vitiligo, alopecia.
  9. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have history of uncontrolled allergic asthma.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    KN046

    Drug: KN046

Interventions

  • DrugKN046

    Phase Ia:Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks. Phase Ib:Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia.

06

What researchers measure

Primary outcomes

  1. In the dose escalation part, number of participants with dose limiting toxicity (DLT).

    Time frame: During the first 4 weeks of treatment.

  2. In the dose expansion part,Objective response rate (ORR).

    Objective response is defined as complete response (CR) or partial response (PR)

    Time frame: up to 2 years.

  3. In the dose expansion part, Duration of response (DoR).

    Duration of response is defined as the time period from the date of initial independent review committee assessed CR or PR until the date of PD or death from any cause, whichever occurs first.

    Time frame: up to 2 years.

07

Study locations

13 sites
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • LINYI Cancer Hospital
    Linyi, Shandong, China
  • Shanghai East Hospital
    Shanghai, Shanghai, China
  • Chengdu Seventh People's Hospital
    Chengdu, Sichuan, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jan 2023, 48 months.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 48 months is close to that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2018
First posted
Nov 7, 2018
StartActual
Dec 18, 2018
Primary completionActual
Jan 3, 2023
CompletionActual
Feb 2, 2023
Last update
Jun 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03733951
Responsible party
Sponsor
First posted
Nov 7, 2018
Start date
Dec 18, 2018
Primary completion
Jan 3, 2023
Completion
Feb 2, 2023
Last update
Jun 9, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Erfonrilimab

Start the discussion